Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 2/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274922 | 0.88 | PARK7 (0.69) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL4624984 | 0.86 | PARK7 (0.63) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL28710147 | 0.84 | PARK7 (0.64) | PARK7CHRM5POLBALDH1A1MEN1 | |
| SCHEMBL29011254 | 0.83 | PARK7 (0.67) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL3027674 | 0.83 | PARK7 (0.63) | PARK7CHRM5POLBALDH1A1MEN1 | |
| SCHEMBL31440735 | 0.82 | PARK7 (0.59) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL11798678 | 0.82 | PARK7 (0.62) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL578232 | 0.81 | PARK7 (0.76) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL2762340 | 0.81 | POLB (0.60) | PARK7CHRM5CA12CA1CA2 | |
| SCHEMBL11150416 | 0.81 | PARK7 (0.64) | PARK7CHRM5CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432388-A1 | AGENT FOR COLOURING FIBRES CONTAINING KERATIN | Henkel Kommanditgesellschaft auf Aktien (DE) | 2004-06-30 | — | — | EP | claimed |
| WO-2003030847-A1 | AGENT FOR COLOURING FIBRES CONTAINING KERATIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2003-04-17 | — | — | WO | claimed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119350241-A | Quinolinone derivative and preparation method and application thereof | 浙江工业大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022240876-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022188045-A1 | METHOD FOR CATALYTIC PREPARATION OF PYRANO[2,3-B]INDOLE-2-ONE COMPOUND | 苏州大学 | 2022-09-15 | — | — | WO | disclosed |
| CN-112961166-B | Catalytic preparation of pyrano [2,3-b]Process for preparing indol-2-one compounds | 苏州大学 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PARK7 1996/4885CHRM5 4877/4885CA12 4824/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PARK7 1996/4885CHRM5 4877/4885CA12 4824/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PARK7 1996/4885CHRM5 4877/4885CA12 4824/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PARK7 1996/4885CHRM5 4877/4885CA12 4824/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | PARK7 2105/4885CHRM5 4879/4885CA12 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.